Advancing Drug Discovery
with iPSC Solutions & Primary Cell Models
Offering iPSCs, primary cells, genome editing, and characterization, we deliver trusted solutions that drive discovery in drug development and disease modeling.
A Collaborative Approach to Off-Target Chemotherapy Toxicity Using Organoids
iXCells has joined an international collaboration with Rosebud Biosciences and Kantify to assess off-target chemotherapeutic toxicity using patient-derived organoids. By combining iXCells’ expertise in cellular reprogramming with advanced 3D organoid platforms and AI-driven analysis, this initiative enables the development of personalized, multi-organ toxicity profiles—supporting safer, more precise oncology research.
Let us help accelerate your next breakthrough.
Backed by proven scientific leadership and integrated human model platforms, iXCells supports more informed translational decisions from discovery through development.
Cell Portfolio
An extensive catalog of human and animal primary cells from healthy and diseased tissues to complement our collection of iPSCs and their derivatives.
PRECLINICAL CRO SERVICES
We offer iPSC reprogramming, Cas9 genome editing, directed differentiation, custom cell isolation, in vitro assays, and ASO screening services. Our team of PhD scientists provides disease-relevant, patent-derived models that accelerate drug discovery and disease understanding.
APPLICATIONS
We specialize in complex assay development and execution for research support. Our expertise includes multi-cellular model building, 3D liver model signaling studies, and compound screening for iPSC-derived neurons and human immune cells.
